fred Saad, MD
University of Montreal Hospital Center · CHUM · Université de Montréal
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name fred Saad, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:51 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05171816 · Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)AstraZeneca · active not recruiting · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph2NCT03764540 · Docetaxel Versus Cabazitaxel Post Abiraterone or EnzalutamideCentre hospitalier de l'Université de Montréal (CHUM) · terminated · Metastatic Prostate Cancer · principal investigator
- Ph3NCT03732820 · Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerAstraZeneca · active not recruiting · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph2NCT00327340 · Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPCAchieve Life Sciences · completed · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.